Posted by Michael Wonder on 11 Apr 2022
Drug pricing with evidence development
11 April 2022 - The policy controversy surrounding aducanumab for Alzheimer disease has shifted from the FDA, which authorised the drug according to very limited evidence of clinical benefit, to Medicare, which has decided to extend insurance reimbursement to beneficiaries only as part of randomised clinical trials.
Medicare’s coverage with evidence development pathway offers to patients the opportunity to access a novel drug if they can enrol in an approved clinical trial.
